Jazz Pharmaceuticals (JAZZ) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

JAZZ · Stock Price

USD 226.96+129.18 (+132.11%)

Market Cap: $14.2B

Historical price data

Market Cap: $14.2BPipeline: 200 drugs (78 Phase 3)Patents: 20Founded: 2003HQ: Dublin, Ireland

Sector Ranking#11 in Rare & Orphan Diseases #94 in Small Molecule Drugs

Overview

Jazz Pharmaceuticals is a global biopharmaceutical company with a mission to develop and commercialize life-changing medicines for patients with rare diseases and unmet needs. The company has achieved significant scale with a market cap of $11.32B, a portfolio of marketed products, and a robust pipeline, driven by a sharpened strategic focus on rare diseases. Its strategy combines internal R&D with disciplined business development to build a sustainable, innovative portfolio, supported by a global commercial footprint and manufacturing infrastructure.

Rare EpilepsiesOncologySleep Disorders

Technology Platform

A diversified therapeutic development and commercialization platform focused on identifying, acquiring, and maximizing the value of medicines in rare diseases and high-need conditions through internal R&D, lifecycle management, and strategic business development.

Pipeline

200

200 drugs in pipeline78 in Phase 3

Drug	Indication	Stage
Sativex + Placebo	Pain	Phase 3
GWP42003-P + Placebo	Seizures Associated With EMAS	Phase 3
Nabiximols	Pain	Phase 3
Sativex + Placebo	Pain	Phase 3
Placebo + Sativex® + THC Alone	Palliative Care	Phase 3

Funding History

4

Total raised:$617M

Debt$500MUndisclosedJun 15, 2014

IPO$90MUndisclosedMay 30, 2007

Series A$27MKohlberg Kravis RobertsJun 15, 2004

SeedUndisclosedUndisclosedJun 15, 2003

FDA Approved Drugs

9

MODEYSONDAAug 6, 2025

ZIIHERABLANov 20, 2024

RYLAZEBLAJun 30, 2021

Opportunities

Significant growth opportunities exist in expanding the labels and geographic reach of its rare disease portfolio, particularly in epilepsy and oncology.

The company's sharpened strategic focus on rare diseases and active business development efforts position it to capitalize on high-value, underserved patient populations.

Risk Factors

Key risks include pipeline execution setbacks, intense competition and pricing pressure in core markets, and portfolio concentration with exposure to patent expirations, particularly for its sleep disorder franchise.

Competitive Landscape

Jazz competes in specialized, high-need markets: in rare epilepsies against other seizure medications and emerging therapies; in oncology against large pharma and biotech in niche indications; and in sleep disorders against generics. Its edge lies in specialized commercialization, rare disease expertise, and strategic asset integration.